Skip to main content
. 2015 Nov;21(11):10.18553/jmcp.2015.21.11.1054. doi: 10.18553/jmcp.2015.21.11.1054

TABLE 4.

Adherence and Persistence to Dabigatran Among Nonswitchers (Used Only Dabigatran During the Follow-Up Period) of Atrial Fibrillation Patients

Follow-up Period Prevalent Cohort Incident Cohort
6 Months 9 Months 12 Months 6 Months 9 Months 12 Months
Number of patients 2,713 1,588 687 364 213 90
Adherence to dabigatran
MPR analysis Mean MPR, mean (SE) 0.73 (0.30) 0.69 (0.33) 0.65 (0.35) 0.72 (0.31) 0.67 (0.33) 0.59 (0.35)
Adherent (MPR ≥ 0.80), n (%) 1,593 (58.7) 847 (53.3) 349 (50.8) 216 (59.3) 109 (51.2) 37 (41.1)
Nonadherent (MPR < 0.80), n (%) 1,120 (41.3) 741 (46.7) 338 (49.2) 148 (40.7) 104 (48.8) 53 (58.9)
Persistence to dabigatran
Main analysis
  Gap = 60 days Nonpersistent, n (%) 854 (31.5) 763 (48.0) 333 (48.5) 130 (35.7) 95 (44.6) 52 (57.8)
Sensitivity analyses
  Gap = 15 days Nonpersistent, n (%) 1,551 (57.2) 1,317 (82.9) 495 (72.1) 212 (58.2) 144 (67.6) 71 (78.9)
  Gap = 30 days Nonpersistent, n (%) 1,203 (44.3) 1,024 (64.5) 417 (60.7) 162 (44.5) 115 (54.0) 58 (64.4)
  Gap = 90 days Nonpersistent, n (%) 600 (22.1) 344 (21.7) 283 (41.2) 94 (25.8) 82 (38.5) 46 (51.1)

Source: IMS Health LifeLink Health Plan Claims Database, 2010-2012.23

MPR = medication possession ratio; SE = standard error.